FACE
24.1.2024 07:01:27 CET | Business Wire | Press release
A survey conducted by YouGov1 and commissioned by the European Federation for Hunting and Conservation (FACE) and partner organisations, has unveiled a significant acceptance of international hunting, often mislabelled as “trophy” hunting.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240123042824/en/
Infographic on Public Opinion on So-Called "Trophy" Hunting in Europe (Photo: FACE – the European Federation for Hunting and Conservation)
The independent sample survey by YouGov2 of over 7000 Europeans from five countries, shows that a majority of EU citizens accept hunting. Only 23% disagree with keeping animal parts, a practice often referred to as “trophy” hunting, whilst 77% either approve or are neutral.
This starkly contrasts the claim that 85% of Europeans oppose “trophy” hunting made by the Humane Society International3. Their misdirection has resulted in several national parliaments initiating efforts to ban “trophy” imports.
The survey, conducted in November 2023, aimed to ascertain unbiased public opinion on the social acceptance of domestic and international hunting. A focus was on the retention of animal parts (e.g. horns, antlers, etc.) as well as the acceptance of legal hunting that benefits conservation.
These findings challenge a narrow perception of hunting as solely targeting "trophies” of charismatic species, as often propagated by animal rights organisations.
Therefore, bans or restrictions on the movement of legally obtained “trophies” are not supported by society, and negatively impact local communities, economies, and biodiversity.
The International Union for Conservation of Nature (IUCN) briefing paper,4 states that “trophy hunting…can and does generate critically needed incentives and revenue for government, private and community landowners to maintain and restore wildlife as a land use and to carry out conservation actions”
For the complete report on the public attitude toward “trophy” hunting, see here.
About Us: FACE – the European Federation for Hunting and Conservation is the voice of 7 million European Hunters and represents 37 national members.
_________________________________
1 All data are provided by YouGov PLC. 7.188 respondents participated in the survey, which took place between the 30.10. and 21.11.2023 in Germany, Italy, Spain, Denmark and Poland. The results were weighted and are representative for the population (age 18+) in the respective country.
2 The survey was conducted by independent polling company YouGov at the request of sustainable use organisations: CIC – International Council for Game and Wildlife Conservation, Safari Club International, Dallas Safari Club, Wild Sheep Foundation, Conservation Force, and the International Professional Hunters Association.
3 https://www.hsi.org/wp-content/uploads/2021/05/eu-trophy-hunting-poll.pdf
4 https://portals.iucn.org/library/efiles/documents/Rep-2012-007.pdf
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123042824/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
